The Impact of PSMA PET-CT on Treatment Decisions in Prostate Cancer – Early Experience in a Single Centre

Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy [1].

Source: Clinical Oncology - March 31, 2020 Category: Radiology Authors: C. Rooney, A. Henry, A. Cole, J. O ’Sullivan, D. Mitchell, S. Jain Source Type: research